Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:NVS On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeNVSNovartis$109.09+0.4%$105.13$92.35▼$120.92$222.06B0.532.07 million shs1.64 million shs12 Stocks Corporate Insiders are AbandoningIf a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceNVSNovartis+0.29%-3.46%+1.26%+10.86%+10.19%Remove AdsCompare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationNVSNovartis2.4579 of 5 stars1.93.02.50.03.40.01.9Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceNVSNovartis 1.80Reduce$123.3813.10% UpsideCurrent Analyst Ratings BreakdownLatest NVS Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails2/13/2025NVSNovartisUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Neutral2/12/2025NVSNovartisMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageUnderweight2/4/2025NVSNovartisDeutsche Bank AktiengesellschaftSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeHold ➝ Buy2/3/2025NVSNovartisBarclaysSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingUnderweight ➝ Underweight(Data available from 3/14/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookNVSNovartis$51.72B4.31$10.88 per share10.03$21.59 per share5.05Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateNVSNovartis$11.94B$5.8818.5512.381.7023.56%37.24%15.85%4/22/2025 (Estimated)Latest NVS EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails1/31/2025Q4 2024NVSNovartis$1.80$1.98+$0.18$1.41$12.86 billionN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthNVSNovartis$2.512.30%+5.34%42.69%N/ALatest NVS DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date2/20/2025NVSNovartis$3.86953/12/20253/12/20253/12/2025(Data available from 1/1/2013 forward)Compare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioNVSNovartis0.481.040.84Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipNVSNovartis13.12%Insider OwnershipCompanyInsider OwnershipNVSNovartis0.01%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableNVSNovartis75,8832.04 billion2.04 billionOptionableNVS HeadlinesRecent News About These CompaniesNFL and Novartis Forge Groundbreaking Health PartnershipMarch 13 at 6:56 PM | devdiscourse.comNFL signs first pharmaceutical deal with NovartisMarch 13 at 6:56 PM | sportsbusinessjournal.comNFL drafts Novartis as league’s first corporate pharma partnerMarch 13 at 6:56 PM | fiercepharma.comNFL signs Novartis as first pharmaceutical partner-sourceMarch 13 at 8:03 AM | reuters.comNovartis Pharmaceuticals and Folia Health Partner on Innovative App-Based Study to Assess Real-World Experience of IgA NephropathyMarch 13 at 8:03 AM | globenewswire.comNovartis Sees Unusually High Options Volume (NYSE:NVS)March 13 at 1:56 AM | americanbankingnews.comTraders Purchase High Volume of Novartis Call Options (NYSE:NVS)March 12 at 5:13 PM | marketbeat.comHopwood Financial Services Inc. Takes $236,000 Position in Novartis AG (NYSE:NVS)March 12 at 7:10 AM | marketbeat.comSaturna Capital Corp Increases Stake in Novartis AG (NYSE:NVS)March 12 at 6:30 AM | marketbeat.comNatural Investments LLC Takes $374,000 Position in Novartis AG (NYSE:NVS)March 12 at 5:50 AM | marketbeat.comProficio Capital Partners LLC Purchases Shares of 224,981 Novartis AG (NYSE:NVS)March 12 at 3:13 AM | marketbeat.comNovartis gains rights to Kyorin’s chronic spontaneous urticaria candidate in deal worth $830mMarch 11 at 11:32 PM | pmlive.comPharma Company Novartis Renews 16K-SF Office at 10 Bryant ParkMarch 11 at 11:32 PM | commercialobserver.comNovartis AG (NYSE:NVS) Shares Sold by PNC Financial Services Group Inc.March 11 at 4:20 AM | marketbeat.comMeriwether Wealth & Planning LLC Invests $821,000 in Novartis AG (NYSE:NVS)March 10, 2025 | marketbeat.comRaymond James Financial Inc. Invests $88.34 Million in Novartis AG (NYSE:NVS)March 10, 2025 | marketbeat.comAigen Investment Management LP Takes Position in Novartis AG (NYSE:NVS)March 10, 2025 | marketbeat.comNaviter Wealth LLC Lowers Stock Position in Novartis AG (NYSE:NVS)March 9, 2025 | marketbeat.comHaven Private LLC Invests $286,000 in Novartis AG (NYSE:NVS)March 8, 2025 | marketbeat.com7,191 Shares in Novartis AG (NYSE:NVS) Acquired by Bradyco Inc.March 8, 2025 | marketbeat.comCallan Family Office LLC Buys 26,973 Shares of Novartis AG (NYSE:NVS)March 8, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeNVS Company DescriptionsNovartis NYSE:NVS$109.09 +0.45 (+0.41%) Closing price 03/13/2025 03:59 PM EasternExtended Trading$109.65 +0.56 (+0.52%) As of 03/13/2025 06:54 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran, a therapy to reduce LDL cholesterol; and Dawn Health for the development and commercialization of Ekiva, a digital solution designed for people living with Paroxysmal Nocturnal Hemoglobinuria. The company was incorporated in 1996 and is headquartered in Basel, Switzerland. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Is a Bottom Finally Forming in Rocket Lab Stock? Intel Stock Surges on New CEO – The Real Story Runs Deeper AMD Stock: Can the PC Refresh Cycle Spark a Rally? Ramaco Resources Pins Hopes on Coal's Untapped Potential Nu Holdings: Is Brazil’s Fintech Leader a Buy at This Discount? Beyond a Market Correction, Moves to Make Now NVIDIA Stock Remains Stunningly Undervalued—Here’s Why Market Overreacts, But Guidewire’s Growth Story Remains Strong Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
